首页> 外文期刊>Current medicinal chemistry-Anti-inflammatory & anti-allergy agents. Anti-inflammatory & anti-allergy agents >Current concepts for optimizing the therapeutic index of glucocorticoid receptor ligands for oral and inhalative use: basic considerations and clinical reality
【24h】

Current concepts for optimizing the therapeutic index of glucocorticoid receptor ligands for oral and inhalative use: basic considerations and clinical reality

机译:优化口服和吸入使用糖皮质激素受体配体治疗指数的当前概念:基本考虑因素和临床现实

获取原文
获取原文并翻译 | 示例
           

摘要

Glucocorticoid receptor agonists are most potent anti-inflammatory agents and indispensable for the treatment of a broad array of inflammatory and immunological disorders. The first compounds introduced into therapy were derived from the natural corticosteroid hydrocortisone. First structural modifications of the core molecule aimed at the increase in selectivity to the glucocorticoid over the mineralocorticoid receptor. Based on a better understanding of structure-activity relationships the next generation of compounds displayed higher receptor affinities and thus higher efficacy. For topically applied glucocorticoids, further progress was achieved by drug targeting, e.g. by inhalation of corticosteroid preparations. Recent developments focussed on the best possible reduction of adverse effects by introducing metabolically labile functional groups into the active molecule to minimize systemic exposure. High affinity to the therapeutic target tissue was recognized as a property that warrants a favorable redistribution kinetics into systemic circulation. These concepts led to a significant improvement of the therapeutic index defined as the ratio of undesired metabolic effects to beneficial anti-inflammatory activity for topically applied glucocorticoids. In contrast, no comparable progress has been achieved for systemically administered glucocorticoids yet. However, new insights into alternate pathways of receptor activation suggest the potential for an agonist-driven differentiation between transactivation and transrepression mechanisms. This molecular effector selectivity gives rise to the hope for the development of compounds exhibiting predominantly therapeutically desired effects. This review discusses structure-property relationships of orally and inhalative administered glucocorticoid receptor ligands with steroidal and non-steroidal structure and their translations into clinically observed efficacy and adverse effects.
机译:糖皮质激素受体激动剂是最有效的抗炎药,对于广泛的炎性和免疫性疾病的治疗是必不可少的。引入治疗的首批化合物源自天然皮质类固醇氢化可的松。核心分子的第一结构修饰旨在增加对盐皮质激素受体的糖皮质激素选择性。基于对结构-活性关系的更好理解,下一代化合物显示出更高的受体亲和力,因此具有更高的功效。对于局部施用的糖皮质激素,通过靶向药物例如通过吸入皮质类固醇制剂。最近的发展集中在通过将代谢不稳定的官能团引入活性分子中以最大程度地减少全身暴露,来最大程度地减少副作用。对治疗靶组织的高亲和力被认为是一种保证向体内循环良好的重新分配动力学的特性。这些概念导致治疗指数的显着改善,治疗指数定义为局部应用糖皮质激素的不良代谢作用与有益抗炎活性的比率。相比之下,全身给药的糖皮质激素尚未取得可比的进展。然而,对受体激活的其他途径的新见解表明,潜在的激动剂驱动的反式激活和反式抑制机制之间的分化。这种分子效应子的选择性为开发显示主要治疗所需作用的化合物带来了希望。这篇综述讨论了口服和吸入给药的糖皮质激素受体配体具有甾体和非甾体结构的结构-性质关系,以及它们对临床观察到的疗效和不良反应的转化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号